TY - JOUR
T1 - Unrelated donor transplant therapy for chronic myelogenous leukemia
AU - McGlave, P.
PY - 1998
Y1 - 1998
N2 - Unrelated donor transplant therapy for chronic myelogenous leukemia is both feasible and effective. As discussed in this article, clinical outcome can be predicted based on several patient characteristics and transplant conditions. Highly selected subsets of patients experience outcomes not appreciably different from recipients of related donor transplants. In many cases, however, unrelated donor transplant is associated with significant peritransplant mortality and other complications. The impact of recent improvements in donor-recipient typing, marrow procurement, graft-versus- host disease prevention and treatment, medical support, and donor selection should soon become apparent.
AB - Unrelated donor transplant therapy for chronic myelogenous leukemia is both feasible and effective. As discussed in this article, clinical outcome can be predicted based on several patient characteristics and transplant conditions. Highly selected subsets of patients experience outcomes not appreciably different from recipients of related donor transplants. In many cases, however, unrelated donor transplant is associated with significant peritransplant mortality and other complications. The impact of recent improvements in donor-recipient typing, marrow procurement, graft-versus- host disease prevention and treatment, medical support, and donor selection should soon become apparent.
UR - http://www.scopus.com/inward/record.url?scp=0031933518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031933518&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(05)70498-6
DO - 10.1016/S0889-8588(05)70498-6
M3 - Article
C2 - 9523227
AN - SCOPUS:0031933518
SN - 0889-8588
VL - 12
SP - 93
EP - 105
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -
